In the latest trading session, 0.8 million Mereo Biopharma Group Plc ADR (NASDAQ:MREO) shares changed hands as the company’s beta touched 0.97. With the company’s most recent per share price at $2.52 changing hands around $0.0 or -0.20% at last look, the market valuation stands at $389.15M. MREO’s current price is a discount, trading about -99.21% off its 52-week high of $5.02. The share price had its 52-week low at $2.47, which suggests the last value was 1.98% up since then.
Analysts gave the Mereo Biopharma Group Plc ADR (MREO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MREO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Mereo Biopharma Group Plc ADR’s EPS for the current quarter is expected to be -0.01.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Instantly MREO was in red as seen in intraday trades today. With action -13.57%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -28.14%, with the 5-day performance at -13.57% in the red. However, in the 30-day time frame, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) is -13.87% down.
The consensus price target for the stock as assigned by Wall Street analysts is 7.5, meaning bulls need an upside of 66.4% from its recent market value. According to analyst projections, MREO’s forecast low is 4 with 8 as the target high. To hit the forecast high, the stock’s price needs a -217.46% plunge from its current level, while the stock would need to soar -58.73% for it to hit the projected low.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
Year-over-year growth is forecast to reach -100.00% down from the last financial year.
5 analysts are of the opinion that Mereo Biopharma Group Plc ADR’s revenue for the current quarter will be 17.28M.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 41.78%. The 2025 estimates are for Mereo Biopharma Group Plc ADR earnings to decrease by -53.57%, but the outlook for the next 5-year period is at 6.69% per year.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 1.6566% or 11.79 million shares worth $42.45 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were Tema ETF Tr-Tema GLP-1, Obesity & Cardiometabolic ETF and Tema ETF Tr-Tema Oncology ETF. With 524.03 shares estimated at $1.31 million under it, the former controlled 0.01% of total outstanding shares. On the other hand, Tema ETF Tr-Tema Oncology ETF held about 0.01% of the shares, roughly 319.01 shares worth around $0.8 million.
